ParkinsonFranceV1, PubMed, Checkpoint, bibRecord, 001785

[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].

Identifieur interne : 001785 ( PubMed/Checkpoint ); précédent : 001784; suivant : 001786

[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].

Auteurs : A. Annic [France] ; D. Devos ; D. Seguy ; K. Dujardin ; A. Destée ; L. Defebvre

Source :

Revue neurologique [ 0035-3787 ]

RBID : pubmed:19150100

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Carbidopa (administration & dosage), Carbidopa (adverse effects), Carbidopa (therapeutic use), Dementia (etiology), Drug Combinations, Dyskinesias (drug therapy), Dyskinesias (etiology), Female, Gait (physiology), Humans, Intubation, Gastrointestinal, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Movement (physiology), Parkinson Disease (drug therapy), Quality of Life.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Carbidopa, Levodopa.
- chemical , adverse effects : Antiparkinson Agents, Carbidopa, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Levodopa.
- drug therapy : Dyskinesias, Parkinson Disease.
- etiology : Dementia, Dyskinesias.
- physiology : Gait, Movement.
- Aged, Drug Combinations, Female, Humans, Intubation, Gastrointestinal, Male, Middle Aged, Quality of Life.

Abstract

When advanced Parkinson's disease (PD) patients experience motor complications (fluctuations and dyskinesias) despite standard oral treatment, two treatment options are available: deep brain stimulation and subcutaneous apomorphine infusion with respects of indications for each strategy. Continuous intraduodenal infusion of levodopa (Duodopa) via a gastrojejunal tube may be proposed at this stage of the disease and the study of indications and clinical results with Duodopa may develop this new therapeutic alternative.

DOI: 10.1016/j.neurol.2008.11.017
PubMed: 19150100

Affiliations:

France

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000B74
to stream PubMed, to step Curation: 000B34

Links to Exploration step

pubmed:19150100

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].</title>
<author><name sortKey="Annic, A" sort="Annic, A" uniqKey="Annic A" first="A" last="Annic">A. Annic</name>
<affiliation wicri:level="1"><nlm:affiliation>EA, IFR, hôpital Roger-Salengro, centre hospitalier et universitaire de Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>EA, IFR, hôpital Roger-Salengro, centre hospitalier et universitaire de Lille</wicri:regionArea>
<wicri:noRegion>centre hospitalier et universitaire de Lille</wicri:noRegion>
<wicri:noRegion>centre hospitalier et universitaire de Lille</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name>
</author>
<author><name sortKey="Seguy, D" sort="Seguy, D" uniqKey="Seguy D" first="D" last="Seguy">D. Seguy</name>
</author>
<author><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name>
</author>
<author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name>
</author>
<author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2009 Aug-Sep</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:19150100</idno>
<idno type="pmid">19150100</idno>
<idno type="doi">10.1016/j.neurol.2008.11.017</idno>
<idno type="wicri:Area/PubMed/Corpus">000B74</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B74</idno>
<idno type="wicri:Area/PubMed/Curation">000B34</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B34</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B34</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B34</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].</title>
<author><name sortKey="Annic, A" sort="Annic, A" uniqKey="Annic A" first="A" last="Annic">A. Annic</name>
<affiliation wicri:level="1"><nlm:affiliation>EA, IFR, hôpital Roger-Salengro, centre hospitalier et universitaire de Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>EA, IFR, hôpital Roger-Salengro, centre hospitalier et universitaire de Lille</wicri:regionArea>
<wicri:noRegion>centre hospitalier et universitaire de Lille</wicri:noRegion>
<wicri:noRegion>centre hospitalier et universitaire de Lille</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name>
</author>
<author><name sortKey="Seguy, D" sort="Seguy, D" uniqKey="Seguy D" first="D" last="Seguy">D. Seguy</name>
</author>
<author><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name>
</author>
<author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name>
</author>
<author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name>
</author>
</analytic>
<series><title level="j">Revue neurologique</title>
<idno type="ISSN">0035-3787</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Carbidopa (administration & dosage)</term>
<term>Carbidopa (adverse effects)</term>
<term>Carbidopa (therapeutic use)</term>
<term>Dementia (etiology)</term>
<term>Drug Combinations</term>
<term>Dyskinesias (drug therapy)</term>
<term>Dyskinesias (etiology)</term>
<term>Female</term>
<term>Gait (physiology)</term>
<term>Humans</term>
<term>Intubation, Gastrointestinal</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Movement (physiology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Quality of Life</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesias</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dementia</term>
<term>Dyskinesias</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Gait</term>
<term>Movement</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Drug Combinations</term>
<term>Female</term>
<term>Humans</term>
<term>Intubation, Gastrointestinal</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Quality of Life</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">When advanced Parkinson's disease (PD) patients experience motor complications (fluctuations and dyskinesias) despite standard oral treatment, two treatment options are available: deep brain stimulation and subcutaneous apomorphine infusion with respects of indications for each strategy. Continuous intraduodenal infusion of levodopa (Duodopa) via a gastrojejunal tube may be proposed at this stage of the disease and the study of indications and clinical results with Duodopa may develop this new therapeutic alternative.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19150100</PMID>
<DateCreated><Year>2009</Year>
<Month>09</Month>
<Day>14</Day>
</DateCreated>
<DateCompleted><Year>2009</Year>
<Month>11</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN>
<JournalIssue CitedMedium="Print"><Volume>165</Volume>
<Issue>8-9</Issue>
<PubDate><MedlineDate>2009 Aug-Sep</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Revue neurologique</Title>
<ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].</ArticleTitle>
<Pagination><MedlinePgn>718-27</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2008.11.017</ELocationID>
<Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">When advanced Parkinson's disease (PD) patients experience motor complications (fluctuations and dyskinesias) despite standard oral treatment, two treatment options are available: deep brain stimulation and subcutaneous apomorphine infusion with respects of indications for each strategy. Continuous intraduodenal infusion of levodopa (Duodopa) via a gastrojejunal tube may be proposed at this stage of the disease and the study of indications and clinical results with Duodopa may develop this new therapeutic alternative.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Seven patients with advanced PD (dementia for all and psychiatric disorders for some of them, axial signs) were treated with Duodopa. We evaluated neuropsychological functions, all UPDRS scales, gait and quality-of-life just before Duodopa onset and six months after treatment end. Moreover, we described all adverse events (early and late) and studied daily levodopa doses before and 6 months after treatment.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We demonstrated an improvement in motor UPDRS (44%), in axial signs (40% for UPDRS part III axial subscore and 12% for gait) and a reduction of fluctuations (37.5%) and in UPDRS part IV dyskinesia (20%). These significant results are observed without any change in the quality-of-life. Adverse events were due to PEG positioning for four patients, the equipment (pump, connection, inner tube) for all patients and levodopa for four patients. Daily levodopa dose had to be increased 13.5%.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Duodopa can be considered as a new treatment strategy providing significant improvements in motor fluctuations, dyskinesia and severe axial signs. These results were demonstrated in very advanced PD patients, who had been excluded from previous studies, with cognitive disorders and for some of them dopaminergic psychosis well controlled by medications.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Annic</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>EA, IFR, hôpital Roger-Salengro, centre hospitalier et universitaire de Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Devos</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Seguy</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Dujardin</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Destée</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Defebvre</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Intérêts de la stimulation dopaminergique continue par Duodopa((R)) dans la maladie de Parkinson évoluée : efficacité et tolérance.</VernacularTitle>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>01</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Rev Neurol (Paris)</MedlineTA>
<NlmUniqueID>2984779R</NlmUniqueID>
<ISSNLinking>0035-3787</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C009265">carbidopa, levodopa drug combination</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber>
<NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002230" MajorTopicYN="N">Carbidopa</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020820" MajorTopicYN="N">Dyskinesias</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005684" MajorTopicYN="N">Gait</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007441" MajorTopicYN="N">Intubation, Gastrointestinal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009068" MajorTopicYN="N">Movement</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>06</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2008</Year>
<Month>09</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>11</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>1</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>1</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>11</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19150100</ArticleId>
<ArticleId IdType="pii">S0035-3787(08)00684-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.neurol.2008.11.017</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
</list>
<tree><noCountry><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name>
<name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name>
<name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name>
<name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name>
<name sortKey="Seguy, D" sort="Seguy, D" uniqKey="Seguy D" first="D" last="Seguy">D. Seguy</name>
</noCountry>
<country name="France"><noRegion><name sortKey="Annic, A" sort="Annic, A" uniqKey="Annic A" first="A" last="Annic">A. Annic</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001785 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001785 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:19150100
   |texte=   [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:19150100" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].

[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki